BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

A lack of information and widespread greenwashing led Transformers to conduct the study, “A Reference for Water Consumption ...

A study commissioned by The Advertising Coalition and conducted by S&P Global Market Intelligence has quantified the impact ...

Adjusted earnings of 75 cents per share beat the Zacks Consensus Estimate of 65 cents. The company registered adjusted ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

The study will look at the housing supply and demand, and it will help the county formulate a plan for addressing its housing ...

A new study from revenue intelligence leader Ebsta finds that the biggest differentiator between top-performing sales teams and the rest isn't more meetings or a bigger pipeline, it's qualification ...

The global cotton market size reached 25.1 Million Tons in 2024. According to IMARC Group, it is projected to reach 28.2 ...

Retail sales rose in June as warm weather boosted fuel and supermarket sales, according to official data. Sales volumes ...

It's widely accepted conventional wisdom that when it comes to creative works—TV shows, films, music, books—consumers crave ...